TAKE A LOOK
AT LASTACAFT
™
For patients with itching
due to allergic conjunctivitis…
• FDA approved to prevent ocular itching all day
1
• Proven to work fast: Effi cacy shown at 3 minutes
2-4
• Proven to last all day: Prevents ocular itching
through 16 hours
2-4
INDICATIONS AND USAGE
LASTACAFT
™
is an H
1
histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Important Safety Information
WARNINGS AND PRECAUTIONS
To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the
dropper tip of the bottle. Keep bottle tightly closed when not in use.
Patients should be advised not to wear a contact lens if their eye is red.
LASTACAFT
™
should not be used to treat contact lens-related irritation.
Remove contact lenses prior to instillation of LASTACAFT
™
. The preservative in LASTACAFT
™
, benzalkonium chloride, may be absorbed by
soft contact lenses. Lenses may be reinserted after 10 minutes following administration of LASTACAFT
™
.
LASTACAFT
™
is for topical ophthalmic use only.
ADVERSE REACTIONS
The most frequent ocular adverse reactions, occurring in < 4% of LASTACAFT
™
treated eyes, were eye irritation, burning and/or stinging
upon instillation, eye redness, and eye pruritus.
The most frequent non-ocular adverse reactions, occurring in < 3% of subjects with LASTACAFT
™
treated eyes, were nasopharyngitis,
headache, and infl uenza. Some of these events were similar to the underlying disease being studied.
Please see adjacent page for brief prescribing information.
©2011 Allergan, Inc., Irvine, CA 92612
™
mark owned by Allergan, Inc.
www.Lastacaft.com APC88VA11 107532
1. LASTACAFT
™
Prescribing Information. 2. Torkildsen G, Shedden A. The safety and effi cacy of
alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.
Curr Med Res Opin. 2011;27(3):623-631. 3. Data on fi le, Allergan, Inc., 2005; Clinical Study Report
05-003-11. 4. Data on fi le, Allergan, Inc., 2005; Clinical Study Report 05-003-13.
Tue Feb 15 17:08:11 PST 2011 - 672062_10x13_x1.ps
